Navidea Biopharmaceuticals Inc  

(Public, NYSEMKT:NAVB)   Watch this stock  
Find more results for OTC:NEOP
1.28
0.00 (0.00%)
Aug 27 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 1.27 - 1.32
52 week 1.11 - 3.02
Open 1.29
Vol / Avg. 684,348.00/504,104.00
Mkt cap 192.81M
P/E     -
Div/yield     -
EPS -0.35
Shares 150.64M
Beta 0.50
Inst. own 37%
Nov 4, 2014
Q3 2014 Navidea Biopharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Aug 6, 2014
Q2 2014 Navidea Biopharmaceuticals Inc Earnings Release
Aug 6, 2014
Q2 2014 Navidea Biopharmaceuticals Inc Earnings Call - Webcast
Jul 17, 2014
Navidea Biopharmaceuticals Inc Annual Shareholders Meeting
Jul 8, 2014
Navidea Biopharmaceuticals Inc Investor Briefing on Sentinel Lymph Node Biopsy in Head & Neck Cancers
Jun 24, 2014
Navidea Biopharmaceuticals Inc at JMP Securities Healthcare Conference
Jun 16, 2014
Navidea Biopharmaceuticals Inc sNDA Approval Conference Call
Jun 5, 2014
Navidea Biopharmaceuticals Inc at Jefferies Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -951.18% -3776.61%
Operating margin -857.51% -3521.10%
EBITD margin - -3363.98%
Return on average assets -145.84% -163.32%
Return on average equity - -
Employees 57 -
CDP Score - -

Address

Suite 300, 425 Metro Place North
DUBLIN, OH 43017-1367
United States - Map
+1-614-7937500 (Phone)
+1-614-7937522 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Navidea Biopharmaceuticals, Inc. (Navidea), formerly Neoprobe Corporation, is a biopharmaceutical company focused on the development and commercialization of precision diagnostic agents. As of December 31, 2011, the Company�s radiopharmaceutical development programs included Lymphoseek (Lymphoseek, Kit for the Preparation of Technetium Tc99m for Injection), a radiopharmaceutical agent for lymph node mapping; AZD4694, an imaging agent, and RIGScan, a tumor antigen-specific targeting agent. In January 2012, the Company executed an option agreement with Alseres Pharmaceuticals, Inc. (Alseres) to license [123I]-E-IACFT Injection, also called Altropane, an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson�s disease, movement disorders and dementia. In August 2011, the Company sold its gamma detection device line of business (the GDS Business) to Devicor Medical Products, Inc.

Officers and directors

Gordon A. Troup Independent Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Thomas H. Tulip Ph.D. President, Chief Business Officer
Age: 61
Bio & Compensation  - Reuters
Michael M. Goldberg M.D. Interim Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Brent L. Larson CPA Chief Financial Officer, Executive Vice President, Treasurer, Secretary
Age: 51
Bio & Compensation  - Reuters
Frederick O. Cope Ph.D. Senior Vice President - Pharmaceutical Research and Clinical Development, Chief Scientific Officer
Age: 67
Bio & Compensation  - Reuters
William J. Regan Senior Vice President - Global Regulatory Affairs and Quality
Age: 62
Bio & Compensation  - Reuters
Cornelia B. Reininger M.D., Ph.D. Senior Vice President, Chief Medical Officer
Age: 61
Bio & Compensation  - Reuters
Eric K. Rowinsky M.D. Director
Age: 57
Bio & Compensation  - Reuters
Peter F. Drake Ph.D. Independent Director
Age: 60
Bio & Compensation  - Reuters
Brendan A. Ford Independent Director
Age: 55
Bio & Compensation  - Reuters